• 1
    Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics CA cancer. J Clin 2011; 61: 6990
  • 2
    Nelson W, DeMarzo A, Isaacs W. Prostate cancer. N Engl J Med 2003; 349: 366381
  • 3
    Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 283294
  • 4
    Hsing A, Sakoda L, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: 843857
  • 5
    Makshida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone replacement. J Urol 2006; 174: 827834
  • 6
    Laukkanen J, Laaksonen D, Niskanen L, Pukkala E, Hakkarainen A, Salonen J. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 16461650
  • 7
    Lund H, Wisløff T, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769774
  • 8
    Beebe-Dimmer J, Dunn R, Sarma A, Montie J, Cooney K. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875881
  • 9
    Beebe-Dimmer J, Nock N, Neslund-Dudas C. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185190
  • 10
    Tande A, Platz E, Folsom A. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 10941102
  • 11
    Martin R, Vatten L, Gunnell D, Romundstad P, Nilsen T. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 11811192
  • 12
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 2001; 285: 24862497
  • 13
    Remzi M, Fong Y, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174: 12561260
  • 14
    D'Amico A, Whittington R, Malkowicz S et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969974
  • 15
    Taskinen M. Is metabolic syndrome the main threat to human health in the twenty-first century? Arterioscler Thromb Vasc Biol 2007; 27: 2275
  • 16
    Ford E, Li C. Physical activity or fitness and the metabolic syndrome. Expert Rev Cardiovasc Ther 2006; 4: 897915
  • 17
    Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 10661076
  • 18
    Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356359
  • 19
    DeNunzio C, Freeland S, Miano R et al. Meatabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 14921498
  • 20
    Blouin K, Despres J, Couillard C et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005; 54: 10341040
  • 21
    Kalyani R, Dobs A. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226234
  • 22
    Pelucchi C, Serraino S, Negri E et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011; 21: 835841
  • 23
    Bonovas S, Filioussi K, Sitaras N. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899904
  • 24
    Mener D, Cambio A, Stoddard D, Martin B, Palapattu G. The impact of HMG-CoA reductase therapy on serum PSA. Prostate 2010; 70: 608615
  • 25
    Loeb S, Kan D, Helfand B, Nadler R, Catalona W. Is statin use associated with prostate cancer aggressiveness? BJU Int 2009; 105: 12221225